These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 18703606)

  • 1. Trastuzumab-resistant breast cancer cells remain sensitive to the auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate.
    Costantini DL; Bateman K; McLarty K; Vallis KA; Reilly RM
    J Nucl Med; 2008 Sep; 49(9):1498-505. PubMed ID: 18703606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS-trastuzumab.
    Costantini DL; Villani DF; Vallis KA; Reilly RM
    J Nucl Med; 2010 Mar; 51(3):477-83. PubMed ID: 20150272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer.
    Costantini DL; Chan C; Cai Z; Vallis KA; Reilly RM
    J Nucl Med; 2007 Aug; 48(8):1357-68. PubMed ID: 17631548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ¹¹¹In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer.
    Fasih A; Fonge H; Cai Z; Leyton JV; Tikhomirov I; Done SJ; Reilly RM
    Breast Cancer Res Treat; 2012 Aug; 135(1):189-200. PubMed ID: 22736376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of Cell Cytotoxicity and Comet Assay on HER2/neu Positive Cell Line Due to
    Piroozfar B; Alirezapour B; Sedeh FM; Mirzaii M; Jalilian AR; Hashemizadeh M; Raisali G
    Curr Radiopharm; 2022; 15(2):148-156. PubMed ID: 34182918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
    Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
    J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer xenografts.
    Costantini DL; McLarty K; Lee H; Done SJ; Vallis KA; Reilly RM
    J Nucl Med; 2010 Jul; 51(7):1084-91. PubMed ID: 20554744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-resistant AML cells and primary AML specimens are killed by 111In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequences.
    Kersemans V; Cornelissen B; Minden MD; Brandwein J; Reilly RM
    J Nucl Med; 2008 Sep; 49(9):1546-54. PubMed ID: 18703602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 111In-labeled immunoconjugates (ICs) bispecific for the epidermal growth factor receptor (EGFR) and cyclin-dependent kinase inhibitor, p27Kip1.
    Cornelissen B; Kersemans V; McLarty K; Tran L; Reilly RM
    Cancer Biother Radiopharm; 2009 Apr; 24(2):163-73. PubMed ID: 19409037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab Labeled to High Specific Activity with (111)In by Site-Specific Conjugation to a Metal-Chelating Polymer Exhibits Amplified Auger Electron-Mediated Cytotoxicity on HER2-Positive Breast Cancer Cells.
    Ngo Ndjock Mbong G; Lu Y; Chan C; Cai Z; Liu P; Boyle AJ; Winnik MA; Reilly RM
    Mol Pharm; 2015 Jun; 12(6):1951-60. PubMed ID: 25919639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Block copolymer micelles target Auger electron radiotherapy to the nucleus of HER2-positive breast cancer cells.
    Hoang B; Reilly RM; Allen C
    Biomacromolecules; 2012 Feb; 13(2):455-65. PubMed ID: 22191486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Favorable tumor uptake and nuclear transport of Auger electrons by nuclear targeting with 111In-trastuzumab in an intraperitoneal tumor mouse model.
    Keiko Li H; Hasegawa S
    Nucl Med Commun; 2022 Jul; 43(7):763-769. PubMed ID: 35506286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [
    Chan C; Fonge H; Lam K; Reilly RM
    Nucl Med Biol; 2020; 80-81():37-44. PubMed ID: 31706737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells.
    Chen P; Wang J; Hope K; Jin L; Dick J; Cameron R; Brandwein J; Minden M; Reilly RM
    J Nucl Med; 2006 May; 47(5):827-36. PubMed ID: 16644753
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Cai Z; Chattopadhyay N; Yang K; Kwon YL; Yook S; Pignol JP; Reilly RM
    Nucl Med Biol; 2016 Dec; 43(12):818-826. PubMed ID: 27788375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab labeled to high specific activity with ¹¹¹In by conjugation to G4 PAMAM dendrimers derivatized with multiple DTPA chelators exhibits increased cytotoxic potency on HER2-positive breast cancer cells.
    Chan C; Cai Z; Reilly RM
    Pharm Res; 2013 Aug; 30(8):1999-2009. PubMed ID: 23615858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptomic Signatures of Auger Electron Radioimmunotherapy Using Nuclear Targeting (111)In-Trastuzumab for Potential Combination Therapies.
    Li HK; Morokoshi Y; Daino K; Furukawa T; Kamada T; Saga T; Hasegawa S
    Cancer Biother Radiopharm; 2015 Oct; 30(8):349-58. PubMed ID: 26447839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ErbB-2 blockade and prenyltransferase inhibition alter epidermal growth factor and epidermal growth factor receptor trafficking and enhance (111)In-DTPA-hEGF Auger electron radiation therapy.
    Cornelissen B; Darbar S; Hernandez R; Kersemans V; Tullis I; Barber PR; Smart S; Vojnovic B; Reilly R; Vallis KA
    J Nucl Med; 2011 May; 52(5):776-83. PubMed ID: 21498540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulation of a kit under Good Manufacturing Practices (GMP) for preparing [
    Chan C; Prozzo V; Aghevlian S; Reilly RM
    EJNMMI Radiopharm Chem; 2022 Dec; 7(1):33. PubMed ID: 36542157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The level of insulin growth factor-1 receptor expression is directly correlated with the tumor uptake of (111)In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin).
    Cornelissen B; McLarty K; Kersemans V; Reilly RM
    Nucl Med Biol; 2008 Aug; 35(6):645-53. PubMed ID: 18678349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.